Article Type
Original Study
Abstract
Control of blood glucose is a key objective in the management of type I and type II diabetes mellitus (DM) as well. The basis for development of new antidiabetic drug is the proper control of the hyperglycemia and further more could manage accompanying disorders especially dyslipidemia. The aim of this study was to investigate a newly developed (33 adrener-gic agonist (BRL 37344) to confirm its effect on blood glucose in two animal models of D.M. which induced by streptozotocin (STZ) in a dose of 70 or 40 mg/Kg for induction of type 1 or type II D.M., respectively and try to explore for the possible underlying mechanism of this effect. Oral admin- istration of BRL 37344 for 4 successive days in either STZ type I or STZ type II diabetic rats produced significant reduction in mean serum glucose level and non-significant change in mean serum insulin level in comparison with non treated STZ diabetic rats. BRL treatment significantly increased glucokinase activity and decreased glucose-6-phosphatase activity in hemogenated hepatic tissues which were isolated from both STZ diabetic rat models. In in-vitro study, BRL produced non-significant changes in insulin secretion from isolated pancreatic tissue of STZ type II diabetic rats, while BRL showed significant increase in glucose uptake by isolated soleus muscle from both STZ
Recommended Citation
A.M., Gaballah; El-Beltagi, Kheriza,; and El-Ashri, Hassan
(2005)
"THE POSSIBLE ANTIDIABETIC ROLE OF SELECTIVE p3 ADRENOCEPTOR AGONIST IN ANIMAL MODELS OF DIABETES MELLITUS.,"
Mansoura Medical Journal: Vol. 34
:
Iss.
2
, Article 11.
Available at:
https://doi.org/10.21608/mjmu.2005.128249
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
